Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Gastroenterol Hepatol ; 20(9): 924-9, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18794608

RESUMO

OBJECTIVES: Host factors and bacterial virulence determinants may play a role in Escherichia coli (E. coli) spontaneous bacterial peritonitis. We evaluated the importance of these factors in the emergence of fluoroquinolone-resistant strains and outcome in cirrhotic patients with E. coli spontaneous bacterial peritonitis. METHODS: E. coli spontaneous bacterial peritonitis was detected in a 2-year period in three tertiary hospitals. Clinical and bacteriological data were obtained. Phylogenetic group and 15 virulence genes of E. coli strains were analyzed by polymerase gene reaction and compared with 50 isolates from pyelonephritis patients. RESULTS: Forty-seven E. coli spontaneous bacterial peritonitis patients were identified, 18 (38%) were fluoroquinolone-resistant, a 12% increase compared with our earlier series from 1997 to 2002. Fluoroquinolone resistance was associated with norfloxacin prophylaxis, increased resistance to trimethoprim-sulfamethoxazole and cefotaxime, and less bacterial virulence, as demonstrated by a higher prevalence of 'nonpathogenic' phylogenetic groups A+B1 (56 vs. 28%; P=0.04) and lower virulence scores in fluoroquinolone-resistant E. coli compared with fluoroquinolone-susceptible E. coli. E. coli strains from cirrhotic patients belonged more frequently to 'nonpathogenic' phylogenetic groups A+B1, had fewer virulence factors and higher rates of fluoroquinolone resistance than isolates from pyelonephytis patients. Immunosuppression was independently associated with in-hospital and 3-month mortality. Bacterial virulence factors were unrelated to mortality. CONCLUSION: Fluoroquinolone-resistant E. coli spontaneous bacterial peritonitis prevalence is increasing because of norfloxacin prophylaxis. Strains from peritonitis are less virulent than strains from pyelonephritis because of a higher prevalence of A+B1 phylogeny and quinolone resistance. Mortality is related to immunosuppression, but not to bacterial virulence factors.


Assuntos
Infecções por Escherichia coli/microbiologia , Escherichia coli/patogenicidade , Peritonite/microbiologia , Adulto , Idoso , Antibacterianos/farmacologia , Antibioticoprofilaxia/efeitos adversos , Farmacorresistência Bacteriana , Escherichia coli/efeitos dos fármacos , Escherichia coli/genética , Infecções por Escherichia coli/imunologia , Feminino , Fluoroquinolonas/farmacologia , Interações Hospedeiro-Patógeno , Humanos , Hospedeiro Imunocomprometido , Cirrose Hepática/complicações , Masculino , Pessoa de Meia-Idade , Peritonite/imunologia , Filogenia , Prognóstico , Estudos Prospectivos , Pielonefrite/microbiologia , Virulência/genética
3.
Eur J Gastroenterol Hepatol ; 14(1): 81-3, 2002 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11782580

RESUMO

Prophylaxis with norfloxacin has been shown to be effective in preventing spontaneous bacterial peritonitis (SBP) in liver cirrhosis. This therapy is associated with the appearance of quinolone-resistant Escherichia coli. However, only four cases of SBP caused by quinolone-resistant E. coli have been reported so far. We present four cases of quinolone-resistant E. coli SBP in three patients receiving oral quinolones, and who were on corticosteroid therapy to treat associated disorders.


Assuntos
Anti-Infecciosos/uso terapêutico , Antibioticoprofilaxia , Infecções por Escherichia coli/diagnóstico , Escherichia coli/efeitos dos fármacos , Cirrose Hepática/complicações , Peritonite/microbiologia , Peritonite/prevenção & controle , Idoso , Anti-Infecciosos/farmacologia , Farmacorresistência Bacteriana , Infecções por Escherichia coli/etiologia , Evolução Fatal , Feminino , Glucocorticoides/uso terapêutico , Hepatite C/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Norfloxacino/farmacologia , Norfloxacino/uso terapêutico , Peritonite/etiologia , Prednisona/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...